Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?

Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide spectrum of clinical behavior. To date, several treatment options are available, whose selection is currently based mainly on clinical criteria. Given the weakness of conventional imaging and PSA assay, the identification of a prognostic and predictive biomarker for choosing the appropriate treatment and monitoring its efficacy is a very topical issue in prostate cancer management. Circulating tumor cells (CTCs) have substantial promise for early tumor diagnosis, disease recurrence and metastatic spread monitoring as well as for biological tumor characterization, thus representing a reliable translational real-time biomarkers of prostate cancer.

This paper summarized the main data available about CTCs detection, their prognostic value, and their potential predictive role for metastatic prostate cancer patients management.

Current drug metabolism. 2017 Jan [Epub]

Chiara Ciccarese, Rodolfo Montironi, Michelangelo Fiorentino, Guido Martignoni, Matteo Brunelli, Roberto Iacovelli, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli, Holger Moch, Giampaolo Tortora, Francesco Massari

Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona. Italy., Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, AOU Ospedali Riuniti, Ancona. Italy., Pathology Service, Addarii Institute of Oncology, S-Orsola-Malpighi Hospital, Bologna. Italy., Department of Pathology and Diagnostic, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Verona. Italy., Department of Surgery and Pathology, Cordoba University Medical School, Cordoba, Spain and Champalimaud Clinical Center, Lisbon. Portugal., Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202. United States., Institute for diagnostic and interventional Radiology, University Hospital Zurich, Zurich. Switzerland., Division of Oncology, S.Orsola-Malpighi Hospital, Bologna. Italy.